Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 5

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 — 617 — — 617 Issuance of Class A common stock for acquisition of assets1,099,992 — 13,541 — — 13,541 Stock-based compensation— — 25,237 — — 25,237 Net loss— — — (27,472)— (27,472)Other comprehensive loss— — — — (82)(82)Balance as of September 30, 2025126,539,546 $2 $2,279,319 $(1,494,339)$138 $785,120 

Common StockAdditional Paid-inCapitalAccumulatedDeficitAccumulatedOther ComprehensiveIncome (Loss)TotalStockholders’EquitySharesAmountBalance as of December 31, 2023119,095,362 $2 $2,025,890 $(1,284,420)$(429)$741,043 Issuance of Class A common stock related to equity awards605,487 — 1,638 — — 1,638 Stock-based compensation— — 36,129 — — 36,129 Net loss— — — (59,949)— (59,949)Other comprehensive loss— — — — (27)(27)Balance as of March 31, 2024119,700,849 $2 $2,063,657 $(1,344,369)$(456)$718,834 Issuance of Class A common stock related to equity awards773,318 — 4,603 — — 4,603 Stock-based compensation— — 38,492 — — 38,492 Net loss— — — (37,897)— (37,897)Other comprehensive income— — — — 26 26 Balance as of June 30, 2024120,474,167 $2 $2,106,752 $(1,382,266)$(430)$724,058 Issuance of Class A common stock related to equity awards565,701 — 156 — — 156 Stock-based compensation— — 33,881 — — 33,881 Net loss— — — (35